IMMUNOMEDICS GRANTED ADDITIONAL PATENT FOR PROPRIETARY TREATMENT OF INFECTIOUS DISEASE

New Discovery Enables Treatment of High-Risk Bacterial, Fungal, Parasitic and Viral Infections

Morris Plains, New Jersey, April 15, 2003 -- Immunomedics, Inc. (Nasdaq:IMMU) today announced the issuance of U.S. patent 6,548,275, covering several of the Company’s proprietary methods and compositions for the treatment of infectious diseases. These methods involve the conjugation of polyclonal antibodies with various therapeutic agents in order to allow selective targeting and delivery of the therapeutics to the site of infection. The therapeutic agents which can be attached to the infection-seeking antibodies include radioisotopes and toxic drugs. The pathogens that can be targeted using this proprietary technology involve all of the major classes of infectious agents, including bacteria such as streptococci, and anthrax; viruses such as HIV, herpes, cytomegalovirus, hepatitis, respiratory syncytial virus, etc.; fungi such as Candida; mycoplasma for example Mycoplasma pneumoniae and protozoa such as malaria.

Cynthia L. Sullivan, the Company’s President and Chief executive Officer, noted “This new patent, and its previously-issued companion patent, 6,319,500, are very timely due to the increased concern raised by the threat of bioterrorism, involving many of the pathogens that are amenable to treatment by these new methods.” “We believe that, while there is still a great deal of work to be done, these technologies, invented by our scientists, will permit safe and effective treatment of many of the pathogens that we most fear. We also have six additional issued patents and still others being prosecuted in the area of infectious disease treatment, thus expanding our intellectual property into indications other than cancer by using our basic antibody platform technology,” Ms. Sullivan commented further. She also stated “this broad portfolio now allows us to seek licensing partners for specific product development.”

Immunomedics is a biopharmaceutical company focused on the development, manufacture and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer and infectious diseases. Integral to these products are highly specific monoclonal antibodies and antibody fragments designed to deliver radioisotopes and chemotherapeutic agents to tumors and sites of infection. Immunomedics has six therapeutic product candidates in clinical trials and has two marketed diagnostic imaging products. The most advanced therapeutic product candidates are LymphoCide® (epratuzumab), which is in Phase II clinical trials for the treatment of non-Hodgkin’s lymphoma, and CEA-Cide® (labetuzumab), which is in Phase I/II clinical trials for the treatment of certain solid tumors.
This release, in addition to historical information, contains forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with the development of novel therapeutic products (including clinical trials outcome and regulatory requirements/actions), competitive risks to marketed biopharmaceutical products and the future availability of financing and other sources of capital, as well as the risks discussed in the Immunomedics’ Annual Report on Form 10-K for the year ended June 30, 2002 on file with the U.S. Securities and Exchange Commission.

Company Contact: Rebecca Kinner, Investor Relations, (973) 605-8200, extension 263. Visit the Immunomedics web site at http://www.Immunomedics.com